Core Viewpoint - Processa Pharmaceuticals, Inc. announced the acceptance of its abstract for PCS499, aimed at treating Focal Segmental Glomerulosclerosis (FSGS), for presentation at the ASN Kidney Week 2025, highlighting the urgency for new therapies in this area [1][4]. Group 1: Presentation Details - The poster for PCS499 will be presented on November 7, 2025, during the session "Glomerular Clinical Trials: From Data to Impact" [2]. - The specific poster board number for the presentation is FR-PO0829 [2]. Group 2: Product Information - PCS499 is an analog of a metabolite of pentoxifylline (PTX), which has shown efficacy in reducing proteinuria but is limited by dose-related side effects [3]. - PCS499 has a favorable safety profile compared to PTX, allowing for higher dosing and potentially greater therapeutic benefits for rare kidney diseases like FSGS [3]. Group 3: Company Overview - Processa Pharmaceuticals focuses on developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, aiming to improve safety and efficacy [6]. - The company modifies existing FDA-approved oncology therapies to enhance their metabolism and distribution while maintaining their cancer-killing mechanisms [6].

Core Insights - Processa Pharmaceuticals, Inc. is participating in the 2025 BIO International Convention to showcase its Next Generation Cancer (NGC) therapies [1][4] - The company will provide updates on its strategic direction and clinical progress, particularly focusing on its lead asset NGC-Cap, which is in a Phase 2 trial for metastatic breast cancer [2][3] - The CEO emphasized the opportunity to engage with potential partners committed to developing safer and more effective cancer treatments [3] Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing NGC drugs that enhance safety and efficacy [5] - The NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to alter metabolism and distribution while maintaining cancer cell-killing mechanisms [5] - The company's strategy combines a novel oncology pipeline with proven active molecules and a Regulatory Science Approach to improve therapy options for cancer patients [5]